Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Instagram Outage Disrupts Thousands of U.S. Users 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
JERSEY, Channel Islands, Feb. 09, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Christopher Lindop as Chief Financial Officer. Mr. Lindop will commence his new role on February 15, 2017.
Mr. Lindop joins Quotient with more than a decade of financial leadership experience within high-growth diagnostic and blood management companies. Most recently, Mr. Lindop served as Chief Financial Officer and Executive Vice President of Business Development at Haemonetics Corporation (NYSE:HAE), a publicly traded hematology management company, where he oversaw financial organization, strategic planning, business development and investor relations during a period of rapid growth. Prior to joining Haemonetics in January 2007, Mr. Lindop served as Chief Financial Officer at Inverness Medical Innovations, now Alere Inc., a publicly traded diagnostics company, where he developed a financial infrastructure to support rapid expansion and led multiple financings. Prior to joining Inverness, Mr. Lindop was a Partner at both Arthur Andersen and Ernst & Young. Mr. Lindop currently serves on the Board of Directors at Parexel International (NASDAQ:PRXL), a publicly traded biopharmaceutical consulting company. Mr. Lindop holds a B.A. in Business from the University of Strathclyde (Scotland).
“We are excited to have Chris join us during such a pivotal period as we work towards the commercial launch of MosaiQTM,” said Paul Cowan, Quotient’s Chairman and Chief Executive Officer. “His vast experience in helping to lead diagnostic and blood management companies through periods of high growth will be invaluable.”
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to address the $3.4 billion global transfusion diagnostics market. The Company's operations are based in Switzerland, Scotland and the US.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Paul Cowan, Chairman & Chief Executive Officer — [email protected]; +1 267 756 0842
